2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 228

Sick Leave and Disability Pension in Working-Age Gout Patients before and after Diagnosis – a Population Based Case-Control Study
Abstract Number: 1753

Signal Transducer and Activator of Transcription (STAT) 3 Regulates Tcrαβ+CD4-CD8- T Cells in Systemic Lupus Erythematosus (SLE)
Abstract Number: 2508

Significant Improvement of Rheumatoid Arthritis (RA) Outcome with Repeat Application of Disease Management (SSDM) Mobiles Tools: A Cohort Study of RA Patients in China
Abstract Number: 696

Significantly Reduced Recurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis during Treatment with Golimumab
Abstract Number: 1302

Silent Progression in Patients with Rheumatoid Arthritis: Is DAS28 Remission an Insufficient Goal in RA? Results from the German Remission-PLUS Cohort
Abstract Number: 2614

Similar Rates of Death, Serious Infections, Cancers, Major Cardiovascular Events in Patients Treated with Abatacept, Rituximab and Tocilizumab: Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis
Abstract Number: 2133

Simulation of Cartilage Damage in Osteoarthritis Using Patient-Derived Induced Pluripotent Stem Cells
Abstract Number: 2548

Single 1g Infusion Vs Double 1g Infusion of Rituximab in Rheumatoid Arthritis in a Large Teaching Hospital: Potential Clinical Benefits and Financial Savings
Abstract Number: 1843

Single Cell Expression Quantitative Trait Loci (eQTL) Analysis of Established SLE-Risk Loci in Lupus Patient Monocytes
Abstract Number: 806

Single Cell Rnaseq Defines a Unique Transcriptome Profile for Myofibroblasts in the Skin of Patients with Systemic Sclerosis
Abstract Number: 2419

Single-Cell Analysis of CD163 mRNA and Protein Expression By Primeflow™ in Polarized Monocyte and Macrophage Populations
Abstract Number: 1615

Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Significantly Improves Physical Function and Reduces Morning Stiffness in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global, Randomized, Placebo-Controlled, Phase 3 Trial
Abstract Number: 672

Sjogren Big Data Project: Influence of Geolocation on the Phenotypic Expression at Diagnosis in 8310 Patients (North-to-South Gradient)
Abstract Number: 673

Sjögren’s Syndrome (SS): The Role of Traditional (SS-A/SS-B) and Novel Antibodies in Diagnosis
Abstract Number: 1216

Sjogren’s Syndrome-Associated Transcripts Show Correlation with Objective Measures of Dryness

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].